“Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multi-centre clinical trial with 4-year follow-up results”
Reginald J. Davis, MD,1 Pierce Dalton Nunley, MD,2 Kee D. Kim, MD,3 Michael S. Hisey, MD,4 Robert J. Jackson, MD,5 Hyun W. Bae, MD,6 Gregory A. Hoffman, MD,7 Steven E. Gaede, MD,8 Guy O. Danielson III , MD,9 Charles Gordon, MD,9 and Marcus B. Stone, PhD2
The prospective randomized, US FDA investigational device exemption pivotal trial of the Mobi-C cervical artificial disc was conducted at 24 centres in the US. Three hundred thirty patients with degenerative disc disease were randomized and treated with cervical total disc replacement (225 patients) or the control treatment, anterior cervical discectomy and fusion (ACDF) (105 patients). Patients were followed up at regular intervals for 4 years after surgery.
The recently published study in the Journal of Neurosurgery and Spine found that at 48 months both groups demonstrated improvement in clinical outcome measures and a comparable safety profile. Data were available for 202 TDR patients and 89 ACDF patients in calculation of the primary endpoint. TDR patients had statistically significantly greater improvement than ACDF patients for the following outcome measures compared with baseline: Neck Disability Index scores, 12-Item Short Form Health Survey Physical Component Summary scores, patient satisfaction, and overall success. ACDF patients experienced higher subsequent surgery rates and displayed a higher rate of adjacent-segment degeneration as seen on radiographs. Overall, TDR patients maintained segmental range of motion through 48 months with no device failure.
Four-year results from this study continue to support TDR as a safe, effective, and statistically superior alternative to ACDF for the treatment of degenerative disc disease at 2 contiguous cervical levels.
To date over 30,000 Mobi-C implantations have taken place worldwide.